{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:59:44Z","timestamp":1790827184381,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11060-025-05230-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T08:51:57Z","timestamp":1759222317000},"page":"1435-1441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report"],"prefix":"10.1007","volume":"175","author":[{"given":"Vaseem M.","family":"Khatri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella A.","family":"Mestres-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenija","family":"Yarlagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Doniparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituraj","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Hsuan Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole O.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma L.","family":"Mahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixa E.","family":"Soyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem H.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha J.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"5230_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-020-05552-2","volume":"180","author":"MN Mills","year":"2020","unstructured":"Mills MN, Figura NB, Arrington JA, Yu HM, Etame AB, Vogelbaum MA, Soliman H, Czerniecki BJ, Forsyth PA, Han HS, Ahmed KA (2020) Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat 180:279\u2013300. https:\/\/doi.org\/10.1007\/s10549-020-05552-2","journal-title":"Breast Cancer Res Treat"},{"key":"5230_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2017.35.15_suppl.1075","volume":"35","author":"N Vidula","year":"2017","unstructured":"Vidula N, Yau C, Rugo HS (2017) Trop2 gene expression (Trop2e) in primary breast cancer (BC): correlations with clinical and tumor characteristics. J Clin Oncol 35:1075\u20131075. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.1075","journal-title":"J Clin Oncol"},{"key":"5230_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Di\u00e9ras V, Phan S, Delaney R, Zhu Y, Tolaney SM (2024) Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 10:33. https:\/\/doi.org\/10.1038\/s41523-024-00635-5","journal-title":"NPJ Breast Cancer"},{"key":"5230_CR4","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/jco.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cort\u00e9s J, Shaughnessy JO, Di\u00e9ras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA (2024) Final results from the randomized phase III ASCENT clinical trial in metastatic Triple-Negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol 42:1738\u20131744. https:\/\/doi.org\/10.1200\/jco.23.01409","journal-title":"J Clin Oncol"},{"key":"5230_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s0140-6736(23)01245-x","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, Tr\u00e9dan O, Ciruelos E, Dalenc F, G\u00f3mez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM (2023) Overall survival with sacituzumab Govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402:1423\u20131433. https:\/\/doi.org\/10.1016\/s0140-6736(23)01245-x","journal-title":"Lancet"},{"key":"5230_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-025-00736-9","volume":"11","author":"T Grinda","year":"2025","unstructured":"Grinda T, Morganti S, Hsu L, Yoo TK, Kusmick RJ, Aizer AA, Giordano A, Leone JP, Hughes M, Tolaney SM, Lin NU, Sammons SL (2025) Real-world outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases. NPJ Breast Cancer 11:22. https:\/\/doi.org\/10.1038\/s41523-025-00736-9","journal-title":"NPJ Breast Cancer"},{"key":"5230_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-021-03735-5","volume":"152","author":"MN Mills","year":"2021","unstructured":"Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA (2021) Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol 152:591\u2013601. https:\/\/doi.org\/10.1007\/s11060-021-03735-5","journal-title":"J Neurooncol"},{"key":"5230_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/jco.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492\u2013516. https:\/\/doi.org\/10.1200\/jco.21.02314","journal-title":"J Clin Oncol"},{"key":"5230_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES, Pike LRG, Seidman AD, Moss N, Beal K, Yu Y (2023) Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases. JAMA Oncol 9:1729\u20131733. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4492","journal-title":"JAMA Oncol"},{"key":"5230_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","volume":"168","author":"Y Koide","year":"2024","unstructured":"Koide Y, Nagai N, Adachi S, Ito M, Kawamura M, Ito M, Ito F, Shindo Y, Aoyama T, Shimizu H, Hashimoto S, Tachibana H, Kodaira T (2024) Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study. J Neurooncol 168:415\u2013423. https:\/\/doi.org\/10.1007\/s11060-024-04681-8","journal-title":"J Neurooncol"},{"key":"5230_CR11","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1158\/1078-0432.CCR-18-2851","volume":"25","author":"PK Stumpf","year":"2019","unstructured":"Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM (2019) Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of Aquaporin-4. Clin Cancer Res 25:3946\u20133953. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2851","journal-title":"Clin Cancer Res"},{"key":"5230_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00711-w","volume":"10","author":"VM Khatri","year":"2024","unstructured":"Khatri VM, Mestres-Villanueva MA, Yarlagadda S, Doniparthi A, Smith DB, Nakashima JY, Bryant JM, Zhao D, Upadhyay R, Mills MN, Oliver DE, Yu HM, Palmer JD, Williams NO, Mahtani RL, Ahluwalia MS, Soliman HH, Han HS, Soyano AE, Kim Y, Kotecha R, Beyer SJ, Ahmed KA (2024) Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases. NPJ Breast Cancer 10:100. https:\/\/doi.org\/10.1038\/s41523-024-00711-w","journal-title":"NPJ Breast Cancer"},{"key":"5230_CR13","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/s1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16:e270\u2013278. https:\/\/doi.org\/10.1016\/s1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"key":"5230_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11060-022-03977-x","volume":"157","author":"MN Mills","year":"2022","unstructured":"Mills MN, King W, Soyano A, Pina Y, Czerniecki BJ, Forsyth PA, Soliman H, Han HS, Ahmed KA (2022) Evolving management of HER2\u2009+\u2009breast cancer brain metastases and leptomeningeal disease. J Neurooncol 157:249\u2013269. https:\/\/doi.org\/10.1007\/s11060-022-03977-x","journal-title":"J Neurooncol"},{"key":"5230_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28:1840\u20131847. https:\/\/doi.org\/10.1038\/s41591-022-01935-8","journal-title":"Nat Med"},{"key":"5230_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrig\u00f3s L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fern\u00e1ndez-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cort\u00e9s J, Braga S (2023) Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol 25:157\u2013166. https:\/\/doi.org\/10.1093\/neuonc\/noac144","journal-title":"Neuro Oncol"},{"key":"5230_CR17","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1016\/j.annonc.2023.09.565","volume":"34","author":"J Tsurutani","year":"2023","unstructured":"Tsurutani J, Jacot W, Yamashita T, Riaz F, Yerushalmi R, Im SA, Niikura N, Halser-Strub U, Cort\u00e9s J, Wennstig AK, Chae Y, Wang X, Li W, Simon H, Masci G, Tamburini E, Aguilar CO, Tecson K, Yung L, Modi S (2023) 388P subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC). Ann Oncol 34:S342\u2013S343. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.565","journal-title":"Ann Oncol"},{"key":"5230_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102924","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cort\u00e9s J (2024) Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-breast03 trial. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102924","journal-title":"ESMO Open"},{"key":"5230_CR19","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1158\/2159-8290.Cd-22-0837","volume":"12","author":"G Jerusalem","year":"2022","unstructured":"Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, Krop IE, Gonz\u00e0lez Farr\u00e9 X, You B, Saura C, Kim SB, Osborne CR, Murthy RK, Gianni L, Takano T, Liu Y, Cathcart J, Lee C, Perrin C (2022) Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. Cancer Discov 12:2754\u20132762. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0837","journal-title":"Cancer Discov"},{"key":"5230_CR20","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM, Ghamasaee P, Sareddy GR, Michalek J, Gilbert AR, Surapaneni P, Tiziani S, Pandey R, Chiou J, Lodi A, Floyd JR, Brenner AJ (2024) Sacituzumab govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun 15:6707. https:\/\/doi.org\/10.1038\/s41467-024-50558-9","journal-title":"Nat Commun"},{"key":"5230_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, Eaton BR, Hattangadi-Gluth JA, Kim MM, Kotecha R, Kraemer L, Li J, Nagpal S, Rusthoven CG, Suh JH, Tom\u00e9 WA, Wang TJC, Zimmer AS, Ziu M, Brown PD (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12:265\u2013282. https:\/\/doi.org\/10.1016\/j.prro.2022.02.003","journal-title":"Pract Radiat Oncol"},{"key":"5230_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf018","author":"KA Ahmed","year":"2025","unstructured":"Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS (2025) Phase II trial of brain MRI surveillance in stage IV breast cancer. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf018","journal-title":"Neuro Oncol"},{"key":"5230_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3171\/2016.10.JNS161036","volume":"128","author":"A Wolf","year":"2018","unstructured":"Wolf A, Kvint S, Chachoua A, Pavlick A, Wilson M, Donahue B, Golfinos JG, Silverman J, Kondziolka D (2018) Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. J Neurosurg 128:23\u201331. https:\/\/doi.org\/10.3171\/2016.10.JNS161036","journal-title":"J Neurosurg"},{"key":"5230_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","volume":"107","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP (2020) Beyond an updated graded prognostic assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys 107:334\u2013343. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5230_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.07.004","volume":"102","author":"I Witzel","year":"2018","unstructured":"Witzel I, Laakmann E, Weide R, Neunhoffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Wurschmidt F, Schem C, Bechtner C, Wurstlein R, Fehm T, Mobus V, Burchardi N, Loibl S, Muller V (2018) Treatment and outcomes of patients in the brain metastases in breast cancer network registry. Eur J Cancer 102:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.004","journal-title":"Eur J Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05230-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:05:06Z","timestamp":1760036706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05230-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5230"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05230-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hsiang-Hsuan Michael Yu has received speaker\u2019s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai and is on advisory boards for Novartis, Eisai, PUMA, Eli Lilly, Astrazeneca. Speaker fees for Merck. Hyo S. Han declares that she has received research funding from Abbvie, Arvinas, Pfizer, Seagen, Zymeworks and Quantum leap healthcare collaborative and on advisory boards for Pfizer and Arvinas. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb, Eli Lilly, Gilead, and Genentech. Rupesh Kotecha has received honoraria from Accuray Inc., Elekta AB, ViewRay Inc., Novocure Inc., Elsevier Inc., Brainlab, Kazia Therapeutics, Castle Biosciences, and Ion Beam Applications and institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, Kazia Therapeutics, and Ion Beam Applications. Reshma Mahtani is a consultant\/advisor for Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Sanofi, Sermonix, Stemline. Manmeet Ahluwalia has received consulting fees from Bayer, Kiyatec, Insightec, GSK, Xoft, Nuvation, SDP Oncology, Apollomics, Prelude, Janssen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem therapeutics, GT Medical Technologies, Allovir, EquilliumBio, QV Bioelectronics, grants to the institution from Seattle Genetics, is on the scientific advisory board of Modifi Biosciences, Bugworks, reports stock in Mimivax, Cytodyn, MedInnovate Advisors LLC, Trisalus Lifesciences, and is on the data safety monitoring committee for VBI Vaccines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}